Natera Inc. has published prospective clinical trial data in Transplantation Direct showing that its Prospera donor-derived cell-free DNA (dd-cfDNA) test allowed over 75 percent of eligible lung transplant patients to safely skip the standard 9-month transbronchial biopsy. The study, conducted by The Ohio State University Wexner Medical Center (OSU-WMC), evaluated the clinical utility of dd-cfDNA surveillance as part of a structured quality initiative to reduce unnecessary invasive procedures post-transplant.

Why real-world biopsy reduction matters in a post-transplant surveillance landscape under pressure

Lung transplantation remains among the most complex and resource-intensive organ transplants. Monitoring for allograft rejection typically involves a rigid biopsy schedule—at one, three, six, nine, and twelve months—regardless of patient-specific risk. These biopsies are not only costly and invasive but also carry a non-negligible risk of complications such as bleeding, pneumothorax, and infection. Given the increasing volume of lung transplants and pressure on hospital throughput, clinicians and administrators alike are searching for safer, more personalized surveillance strategies.

The OSU-WMC trial provides new evidence supporting a paradigm shift from fixed-interval biopsies toward risk-adapted, biomarker-driven monitoring. The integration of Prospera into an institutional quality assurance and performance improvement (QAPI) framework represents a noteworthy attempt to systematize this shift. Over a one-year period, 78 lung transplant recipients were monitored using Prospera, with dd-cfDNA levels guiding the decision to omit the routine 9-month biopsy in clinically stable, low-risk patients.

Industry observers note that while the study’s sample size remains modest, its implications are substantial. The absence of significant differences in acute rejection, spirometry, and donor-specific antibody levels between those who skipped the biopsy and those who underwent it suggests that Prospera’s risk stratification may hold real clinical value.

What this confirms about dd-cfDNA’s role in enabling precision transplant care

The Prospera assay, developed by Natera, detects cell-free DNA fragments originating from the donor organ circulating in the recipient’s blood. Elevated levels of dd-cfDNA signal cellular injury and may indicate early allograft rejection—even in asymptomatic patients. While this concept is not new, its integration into protocol-based care pathways is only now starting to take hold, especially in the lung transplant space where inflammation, infection, and sample variability complicate clinical decision-making.

In the OSU-WMC study, a dd-cfDNA threshold of <1.0 percent was used to define low-risk status. Approximately three-quarters of patients fell below this level and were spared the 9-month biopsy without adverse outcomes. By the 12-month follow-up, 95 percent of those who had skipped the biopsy had not developed clinically significant rejection.

This finding supports what clinicians tracking the space have long suspected: that traditional biopsy schedules may be overutilized in the modern immunosuppressive era, and that noninvasive molecular assays could triage patients more effectively. If further validated, such an approach could reduce unnecessary biopsies while maintaining, or even improving, clinical vigilance.

How transplant centers could benefit from risk-adapted biopsy strategies

The operational burden of routine biopsies extends beyond patient discomfort. Bronchoscopic biopsies consume significant procedural capacity, often require post-procedure monitoring, and can delay throughput in transplant centers. For resource-constrained or high-volume institutions, eliminating even one routine biopsy per patient could yield meaningful gains.

Clinical assistant professor Dr. Justin Rosenheck, the study’s lead investigator at OSU-WMC, emphasized that Prospera-guided decision-making enhanced both the patient experience and the sustainability of transplant programs. His framing highlights a growing institutional appetite for diagnostic tools that can deliver outcome-neutral procedural de-escalation.

The fact that this trial was conducted as part of a formal QAPI process further lends it weight. Quality improvement frameworks are increasingly serving as test beds for implementing biomarker-guided care pathways. If transplant programs begin to systematically replace protocol biopsies with validated molecular markers like dd-cfDNA, reimbursement frameworks and quality metrics may need to evolve in tandem.

Where Prospera sits within the competitive dd-cfDNA transplant testing space

Natera is one of several companies operating in the dd-cfDNA transplant diagnostics segment. Others include CareDx with its AlloSure assay and Eurofins Transplant Genomics with TruGraf and Viracor. While CareDx has led adoption in kidney and heart transplant monitoring, Natera’s Prospera test is gaining traction due to its broad organ applicability and support by over 350 peer-reviewed publications across different organ types.

What differentiates this study is its lung transplant focus, a domain that has traditionally lacked robust molecular surveillance tools due to the complexity of the pulmonary immune environment. The ability of Prospera to deliver actionable risk assessments in this context provides a potential competitive edge.

However, comparative studies between these platforms remain limited, and institutional preferences often depend on bundled service contracts, logistics, and familiarity with the technology. For Natera to secure deeper penetration into lung transplant programs, further multi-center validation and payer-aligned health economic data will be essential.

What still limits guideline adoption of dd-cfDNA-based surveillance

Despite these encouraging findings, Prospera and its peers face key barriers to widespread adoption. Notably, the trial was observational and conducted within a single academic medical center. Clinician discretion, patient selection, and QAPI-specific workflows may limit its generalizability across community transplant programs or centers with different surveillance philosophies.

There are also open questions about the optimal dd-cfDNA thresholds across transplant indications and rejection types. For instance, the 1.0 percent cutoff used in this study may not capture low-grade or chronic rejection patterns that progress insidiously. Moreover, dd-cfDNA performance can be affected by infection, ischemia-reperfusion injury, or sampling timing post-transplant, introducing potential for false positives or negatives.

From a regulatory standpoint, industry watchers point out that while these tests are offered under CLIA regulations, they are not FDA-approved companion diagnostics. For dd-cfDNA to move from adjunct to anchor in post-transplant monitoring, more rigorous studies—ideally randomized trials—will be needed.

What happens next if biopsy reduction becomes standard in organ health surveillance

Should the trend toward biopsy-free surveillance continue, it may redefine the entire architecture of post-transplant care. Molecular diagnostics like Prospera could become core components of transplant protocols, reducing reliance on invasive procedures while enabling earlier intervention for those at higher risk.

For Natera, this would signal an opportunity to expand the Prospera franchise beyond lung, heart, and kidney into composite transplant care models. This could involve integration with donor-specific antibody profiling, gene expression signatures, and AI-enabled risk scoring. Commercially, such positioning would elevate Prospera from test to platform.

Clinicians and payers alike will be watching for multisite replication of the OSU-WMC findings and for studies that quantify cost offsets related to reduced procedural burden. In parallel, transplant societies and regulatory bodies may consider whether guideline updates are warranted in light of these emerging data.

While full-scale paradigm change will require more evidence, this study represents a meaningful first step in transplant diagnostics modernization—where safety, scalability, and molecular precision converge.

  biopsy reduction, dd-cfDNA, donor-derived cell-free DNA, lung transplantation, Natera, OSU Wexner Medical Center, Prospera test, QAPI, transplant diagnostics